Human tumor antigens, immunosurveillance, and cancer vaccines (original) (raw)

• Finn OJ, Lotze MT: A decade in the life of tumor immunology. Clin Cancer Res 2001;7:759s-760s.
  PubMed CAS Google Scholar
• Finn OJ: Tumor-rejection antigens recognized by T lymphocytes. Curr Opin Immunol 1993;5:701–708.
  Article PubMed CAS Google Scholar
• Barnd DL, Lan MS, Metzgar RS, Finn OJ: Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989;86:7159–7163.
  Article PubMed CAS Google Scholar
• Finn OJ: Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630–641.
  Article PubMed CAS Google Scholar
• Graziano DF, Finn OJ: Tumor antigens and tumor antigen discovery. Cancer Treat Res 2004;123:89–111.
  Google Scholar
• Kao H, Amoscato AA, Ciborowski P, Finn OJ: A new strategy for tumor antigen discovery based on in vitro priming of naive T cells with dendritic cells. Clin Cancer Res 2001;7:773s-780s.
  PubMed CAS Google Scholar
• Kao H, Marto JA, Hoffmann TK, et al: Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001;194:1313–1323.
  Article PubMed CAS Google Scholar
• Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ: MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004;82:249–293.
  Article PubMed CAS Google Scholar
• Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ: The mechanisms of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 2000; 165:3730–3741.
  PubMed CAS Google Scholar
• Hiltbold EM, Ciborowski P, Finn OJ: Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+T cells. Cancer Res 1998;58:5066–5070.
  PubMed CAS Google Scholar
• Hiltbold EM, Alter MD, Ciborowski P, Finn OJ: Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. Cell Immunol 1999;194:143–149.
  Article PubMed CAS Google Scholar
• Vlad AM, Muller S, Cudic M, et al: Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 2002;196:1435–1446.
  Article PubMed CAS Google Scholar
• Soares MM, Mehta V, Finn OJ: Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 2001;166:6555–6563.
  PubMed CAS Google Scholar
• Cramer DW, Titus-Ernstoff L, McKolanis JR, et al: Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1125–1131.
  Article PubMed CAS Google Scholar
• Carlos CA, Dong HF, Howard OM, Oppenheim JJ, Hanisch FJ, Finn OJ: Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol 2005;175:1628–1635.
  PubMed CAS Google Scholar
• Suzuki H, Graziano DF, McKolanis J, Finn OJ: T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005;11:1521–1526.
  Article PubMed CAS Google Scholar
• Yu M, Zhan Q, Finn OJ: Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol Immunol 2002;38:981–987.
  Article PubMed CAS Google Scholar
• Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT: A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996;63:298–304.
  Article PubMed CAS Google Scholar
• Ramanathan RK, Lee KM, McKolanis J, et al: Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005;54:254–264.
  Article PubMed CAS Google Scholar
• Schmielau J, Finn OJ: Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001;61:4756–4760.
  PubMed CAS Google Scholar
• Schmielau J, Nalesnik MA, Finn OJ: Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 2001; 7:933s-939s.
  PubMed CAS Google Scholar
• Finn OJ: Premalignant lesions as targets for cancer vaccines. J Exp Med 2003;198:1623–1626.
  Article PubMed CAS Google Scholar
• Finn OJ: Immune response as a biomarker for cancer detection and a lot more. N Engl J Med 2005;353:1288–1290.
  Article PubMed CAS Google Scholar
• Egloff AM, Weissfeld J, Land SR, Finn OJ: Evaluation of anticyclin b1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Ann N Y Acad Sci 2005;1062:29–40.
  Article PubMed CAS Google Scholar